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most probably need a graft different
from one destined to replace failing
myocardium in a 75-year-old patient.
5. With respect to the cells, Wagers and
associates5 have demonstrated that
bone marrow stem cells have little
developmental plasticity. Most of the
tissue engineering approaches with
bone marrow stem cells use whole
bone marrow, rather than specific
subpopulations of it, and they fre-
quently lack identification of the in-
oculated cells because of missing la-
beling and reliable colocalization
studies. What are we implanting?
What happens to each particular cell
population, and to what extent do
these cells transdifferentiate into car-
diomyocytes? Studies with myo-
blasts do no better. Reliability and
interpretability of the results would
be significantly enhanced if cell la-
beling and tracking methods would
be used routinely. Some worth men-
tioning are the green fluorescent pro-
tein or carboxyfluorescein diacetate
succinimidyl ester methods, the
membrane fluorescent intercalated
dye pkh26-gl method, and colocal-
ization or confocal studies to identify
cell identity, location, differentiation
status and host immune response
(Figure 1).
The commentary of this group will cer-
tainly initiate fruitful discussion on basic
requirements for future scientific ap-
proaches to restoring injured myocardium.
Theo Kofidis, MD
Leora B. Balsam, MD
Robert C. Robbins, MD
Cardiothoracic Surgery/Falk Research Center
Stanford University Medical School
Stanford, CA 94305
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Reply to the Editor:
The letter of Kofidis and colleagues from
Stanford University highlights several key
issues that face regenerative medicine as it
applies to the heart. Their insightful per-
spective will help spawn the critical discus-
sion that is required to fulfill the promise of
restoring cardiac structure and function af-
ter cardiac injury. Although we agree that
engineered biomaterial cell-seeded patches
and cellular transplantation are developing,
less than a decade ago heart regeneration
was considered science fiction. We hope
that this discussion will generate more di-
rected research in this emerging discipline.
With respect to cardiac geometry, living
ventricular muscle constitutes a complex
helical structure. It will be ideal to repair
myocardial scar tissue or ventricular de-
fects with asymmetric and anisotropic mus-
cle tissue. However, scar tissue at site of
reconstruction of ventricular aneurysm and
synthetic material used for repair of con-
genital defects is not helical and lacks con-
tractility and growth potential. An autolo-
gous cell-seeded conduit grows with the
child1 when used during correction of con-
genital defects and may reduce the need for
reoperation. Similarly, in large ventricular
aneurysms in which resection needs to be
complemented with a patch, autologous
cell-seeded biomaterials2 may be prefera-
ble to the static materials currently used,
such as pericardium, polytetrafluoroethyl-
ene, and Dacron polyester fabric.
Tissue engineering with cell-seeded
biodegradable materials is a novel technol-
ogy that allows the growth of muscle cells
in three dimensions to regenerate injured
muscle. The biodegradable material does
not repair injured heart segments; rather,
the biomaterial gradually degrades, and it
is the cells in the biomaterial that secrete
extracellular matrix proteins, stimulate an-
giogenesis, and form tissue resembling
myocardial tissue.3,4 The resulting tissue is
fed by neovasculature and consists of mus-
cle as well as a complex matrix that inter-
digitates with the host myocardium. Al-
though the graft is initially isotropic, it
mediates an increase in elasticity and
strength of the scar tissue, prevents scar
expansion, and halts ventricular dilation.2
In addition, the engineered graft will re-
model in response to ventricular pressure
and stretch. Cellular hyperplasia and hy-
pertrophy will enhance the strength of the
graft as the biomaterial degrades. Impor-
tantly, the new muscle tissue has growth
potential and would reduce the necessity
for reoperation.1,3,5
With respect to cardiac hemodynamics,
early biomaterials were unable to withstand
wall stress of the left ventricle. However,
modification of the biomaterials has in-
creased their strength. We have evaluat-
ed2,4 a composite biomaterial consisting of
a spongy central core made of 50% -cap-
rolactone and 50% L-lactic acid that en-
courages tissue ingrowth. The outer layers
are reinforced with knitted poly-L-lactide
fabric, which provides sufficient strength to
prevent disruption when placed in the left
ventricle. The exciting feature of this new
biomaterial is that the spongy portion,
which supports the initial cell inoculum, is
absorbed within 2 months and the fibrous
portion, which provides the strength, per-
sists for 1 to 2 years. We have shown that
smooth muscle cells seed and survive
within this material in vitro and form mus-
cle tissue in vivo.3 The modified biomate-
rial continued to withstand right ventricular
pressures at 6 months after implantation.5
We also used the cell-engineered graft
(poly-L-lactide fabric with smooth muscle
cells) to repair transmural defects of left
ventricular free wall in adult rat hearts after
myocardial infarction. The graft withstood
left ventricular pressures and prevented
ventricular dilation in this model.2 A sim-
ilar material was used as an autologous
cell-seeded patch in the repair of a congen-
ital defect.1
These promising results will need to be
evaluated in larger animal models that re-
quire thicker and more extensive grafts.
The thicker grafts may be limited by the
extent of tissue ingrowth in vitro and of
neovascularization in vivo. The use of de-
cellularized tissue provides the promise of
a preformed vascular supply. However, the
existing structure of the material will be
quickly dissolved by the remodeling pro-
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cess, and cell survival will depend on the
graft’s ability to attract neovascularization.
Whereas the field of therapeutic angiogen-
esis remains nascent, both mechanical sup-
port and vascular supply to the engineered
graft could be enhanced by surgical strate-
gies such as the placement of a pedicled
muscular graft around the biomaterial.
With respect to microscopic structure,
the microscopic appearance before imple-
mentation is rapidly altered by the remod-
eling process after engraftment. Preformed
channels for nerves, arterioles, and lym-
phatics are rapidly replaced by host and
transplanted cells, remodeling the region in
response to chemical, electrical, physical,
and hemodynamic stimuli.
With respect to electrical properties,
those of the newly formed muscle tissue
require further characterization. Skeletal
myoblast implantation resulted in an in-
creased risk of ventricular arrythmia after
bypass grafting and autologous cell trans-
plantation in patients with ischemic cardio-
myopathy.6 Although this presents a hurdle
to be overcome, it also provides the poten-
tial to convert electrically inert scar to tis-
sue that is capable of passively conducting
action potentials. Indeed, preliminary ex-
periments in our laboratory have demon-
strated that a QRS complex can be detected
in a cell-transplanted scar where it had
been electrically silent before implantation
(unpublished observations). The electrical
resynchronization may improve systolic
performance, as reported from many cen-
ters, in the absence of myogenesis. Similar
to the process by which multisite pacing
has been shown to improve systolic func-
tion,7 cell transplantation may improve he-
modynamics by allowing the entire myo-
cardium to beat in unison again.
With respect to issues of storage, con-
servation, and scale, we agree that a child
with a congenital defect will need a differ-
ent graft than a 75-year-old patient with a
ventricular aneurysm. There is no question
that a variety of grafts need to be developed
to tailor the surgical strategy to the patient.
The autologous cell-seeded tissue engi-
neered patch uses the component cells for
repair. Aside from the choice of biomate-
rial, therefore, the tissue-engineered graft
can be seeded with various combinations of
cell types.
With respect to the cells, issues vary by
cell type. Because congenital cardiac de-
fects can be diagnosed in the fetal stage,
umbilical cord blood cells could be used to
engineer tissue.8,9 Experience with this cell
type, however, is limited.
Bone marrow contains stem cells that
can differentiate into myogenic cells with
proper induction.10,11 In fact, bone marrow
mesenchymal stem cells have extensive
plasticity and have the potential to recreate
all of the cell types in the heart. Because
the tissue is easily obtained, these cells are
excellent candidates for autologous tissue
engineering.
Skeletal myoblasts have been used for
cell transplantation to repair damaged
hearts.6 The animal data and clinical trials
have been relatively encouraging. The im-
planted cells formed muscle tissue in the
myocardial scar tissue and improved heart
function. These cells can certainly be used
for autologous tissue engineering.
Smooth muscle cells represent another
candidate cell type for tissue engineering.
The smooth muscle cells can be harvested
from a number of sources in the patient to
construct an autologous cell patch. The
cells are easily cultured, should induce an-
giogenesis in the graft, and can respond to
in vivo mechanical stretch by hyperplasia
and hypertrophy to prevent patch dilatation
and thinning.2,5
With respect to cell fate, the fate of the
transplanted cells and the mechanism by
which they enhance myocardial function
remain largely unknown. We agree with
Kofidis and colleagues that appropriate
tracking methods, such as those presented
in their letter, will aid in answering these
questions.
An equally important issue is the role
that the host’s immune response plays in
the field of cell transplantation and bioma-
terial engineering. This has been an oft
neglected issue. Recent evidence from our
laboratory indicates that even transplanta-
tion of syngeneic cells grown in vitro for 2
weeks elicits a response that includes T-
and B-cell infiltration (unpublished obser-
vations). The appropriate modulation of the
immune response may improve the already
promising results of cell transplantation.
In closing, we are grateful to Kofidis
and colleagues for bringing these important
issues to critical discussion. The area of
regenerative medicine is promising and in
our mind forms the basis for our future
therapies. Although we have a long way to
go, we must not forget that we have come
an even longer way, in spite of the Achilles
heels.
Shafie Fazel, MD, MSc
Richard D. Weisel, MD
Ren-Ke Li, MD, PhD
Division of Cardiac Surgery
Department of Surgery
Toronto General Research Institute
Toronto General Hospital
University of Toronto
Toronto, Ontario, Canada
References
1. Shin’oka T, Imai Y, Ikada Y. Transplanta-
tion of a tissue-engineered pulmonary ar-
tery. N Engl J Med. 2001;344:532-3.
2. Matsubayashi K, Fedak PW, Mickle DA,
Weisel RD, Ozawa S, Li RK. Improved left
ventricular aneurysm repair with bioengi-
neered vascular smooth muscle grafts. Cir-
culation. 2003;108(10 Suppl 1):II219-25.
3. Ozawa T, Mickle DA, Weisel RD, Koyama
N, Wong H, Ozawa S, et al. Histologic
changes of nonbiodegradable and biode-
gradable biomaterials used to repair right
ventricular heart defects in rats. J Thorac
Cardiovasc Surg. 2002;124:1157-64.
4. Ozawa T, Mickle DA, Weisel RD, Koyama
N, Ozawa S, Li RK. Optimal biomaterial for
creation of autologous cardiac grafts. Circu-
lation. 2002;106(12 Suppl 1):I176-82.
5. Ozawa T, Mickle DA, Weisel RD, Matsuba-
yashi K, Fujii T, Fedak PW, Koyama N, et
al. Tissue engineered grafts matured in the
right ventricular outflow tract. Cell Trans-
plant. In press.
6. Menasche P, Hagege AA, Vilquin JT, Des-
nos M, Abergel E, Pouzet B, et al. Autolo-
gous skeletal myoblast transplantation for
severe postinfarction left ventricular dys-
function. J Am Coll Cardiol. 2003;41:1078-
83.
7. Yu CM, Lin H, Fung WH, Zhang Q, Kong
SL, Sanderson JE. Comparison of acute
changes in left ventricular volume, systolic
and diastolic functions, and intraventricular
synchronicity after biventricular and right
ventricular pacing for heart failure. Am
Heart J. 2003;145:E18.
8. Hoerstrup SP, Kadner A, Breymann C,
Maurus CF, Guenter CI, Sodian R, et al.
Living, autologous pulmonary artery con-
duits tissue engineered from human umbili-
cal cord cells. Ann Thorac Surg. 2002;74:
46-52.
9. Kadner A, Hoerstrup SP, Tracy J, Breymann
C, Maurus CF, Melnitchouk S, et al. Human
umbilical cord cells: a new cell source for
cardiovascular tissue engineering. Ann Tho-
rac Surg. 2002;74:S1422-8.
10. Shake JG, Gruber PJ, Baumgartner WA,
Senechal G, Meyers J, Redmond JM, et al.
Mesenchymal stem cell implantation in a
swine myocardial infarct model: engraft-
ment and functional effects. Ann Thorac
Surg. 2002;73:1919-25.
11. Tomita S, Mickle DA, Weisel RD, Jia ZQ,
Letters to the Editor
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 6 2115
Tumiati LC, Allidina Y, et al. Improved
heart function with myogenesis and angio-
genesis after autologous porcine bone mar-
row stromal cell transplantation. J Thorac
Cardiovasc Surg. 2002;123:1132-40.
doi:10.1016/j.jtcvs.2003.03.003
Coagulation, fibrinolysis, and cell
activation in patients and in shed
mediastinal blood during coronary
artery bypass grafting with a new
heparin-coated surface
To the Editor:
Johnell and colleagues1 recently reported
the improved biocompatibility of a new
heparin-coated surface. They also pre-
sented results after modifications of the an-
ticoagulation protocol. They concluded
that a low dose of systemic heparin might
not be sufficient to maintain the antithrom-
botic activity and that a high dose resulted
in increased blood activation.
The design of the study merits discus-
sion; otherwise, the conclusion might be
misunderstood. In particular, the reduction
of anticoagulation, even combined with a
thromboresistant extracorporeal circuit,
might appear detrimental for patients un-
dergoing cardiopulmonary bypass (CPB).
The basis for a safe low anticoagulation
protocol in combination with heparin-
coated CPB circuits was described by Al-
dea and associates2 in 1998. It includes
many parameters derived from the scien-
tific literature from the 1990s, such as con-
trolled suction with cell-saving devices al-
lowing washing before retransfusion,
limitation of air-blood contact with closed
circuits, specifically adapted anticoagula-
tion through precise heparin and protamine
titration, low prime volume facilitated by
retrograde autologous prime, and normo-
thermia. This tailored approach of CPB,
adopted by our own center, has been found
clinically beneficial3 and is therefore justi-
fied for routine surgical practice. One of the
most important parameters omitted by the
authors in the management of a low hepa-
rinized CPB is the retransfusion of highly
activated blood into the circulation because
cardiotomy suction has been used. The
contact of blood with air or with the surgi-
cal field through the tissue pathway is fol-
lowed by activation of inflammation and
hemostasis disturbances, despite the use of
a significant amount of fluid heparin, which
appears to be an unperfected anticoagulant
for CPB although it is universally used.
When a cell-saving device is used instead
of cardiotomy suction, all the different
markers of blood activation are excluded
and not retransfused into the circulation.
With this approach, it has been proved that
circulating F12 levels do not correlate
with activated clotting time (the lowest ac-
tivated clotting time does not imply the
highest F12) and that a low anticoagulation
protocol is safe for the patient.2 Therefore
some of the results presented by Johnell and
colleagues1 need to be taken with caution.
On the other hand, the study of Johnell
and colleagues1 provides important data
about the detrimental effects of heparin,
which could justify a low anticoagulation
protocol. Evidence of proinflammatory and
procoagulant effects of high-dose heparin
was found, as in previous reports. The re-
duction of heparin dose during CPB with
heparin-coated circuits reduces leukocyte
adhesion on artificial surfaces4 and better
preserves antithrombin III levels.5 In addi-
tion, low anticoagulation requires a low
dose of protamine for titration and reduces
the amount of heparin-protamine com-
plexes known to activate the classic path-
way of complement cascade.
The biocompatibility of new equipment
must be assessed, particularly with respect
to thromboresistance. Johnell and col-
leagues1 successfully demonstrated the re-
duction of contact activation. However, it
is fundamental that the experimental design
respect some principles that have been pre-
viously elucidated when they are expected
to be of major importance in the outcome.
This is particularly true if CPB is managed
with low anticoagulation.
Christophe Baufreton, MD, PhD
Jean Louis de Brux, MD
Department of Cardiac Surgery
University Hospital of Angers
Angers, France
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Myogenesis after myocardial stem
cell transplantation
To the Editor:
I read the article of Chedrawy and col-
leagues,1 “Incorporation and Integration of
Implanted Myogenic and Stem Cells Into
Native Myocardial Fibers: Anatomic Basis
for Functional Improvements,” in the Jour-
nal with great interest. Chedrawy and col-
leagues1 described regenerated isogenic
myofebrile grafts injected into nonischemic
normal myocardium. By 4 to 6 weeks, fully
differentiated myocytes could be seen to
interconnect among native cardiomyo-
cytes. The authors attributed this desirable
incorporation to cell-cell electromechanical
junction. However, in a clinical setting
with scar tissue and akinetic ventricular
wall, the microenvironment is not condu-
cive to electromechanical activity to induce
a desirable environment to trigger pheno-
typic changes for transplanted cells. Is it
possible that cytokines, such as transform-
ing growth factor  or insulin growth fac-
tor, generated because of the presence of
macrophage and monocytes, play a role in
the genesis of proliferation and transforma-
tion of new myofibrils?
Syde Taheri, MD
9095 Main St
Suite C
Clarence, NY 14031
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